Olweus and colleagues identify a T cell receptor reactive against the recurrent D835Y driver mutation in FLT3 in acute myeloid leukemia and show that engineered T cells against this neoantigen provide efficient immunotherapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.